APPLICABILITY OF BIOMEDICAL PRODUCTS IN PATIENTS WITH DIABETIC FOOT SYNDROME

Fast and cost-effective treatment of patients with diabetic foot syndrome (DFS) is still a great challenge today. The use of biomedical cell products (BCP) in this category of patients has its own pathogenetic orientation, however, it remains not fully understood and accepted. This review presents the results of numerous studies confirming the effectiveness of the use of BCP for the treatment of mainly superficial trophic defects in patients with neuropathic form of DFS. However, these technologies are still behaved to adjuvant therapies. There are no clear algorithms and regulations for the use of BCP in patients with DFS. It was shown that use of BCP accelerates the reparative processes of superficial trophic defects in patients with neuropathic form of DFS in combination with standard therapy and reduces the time of wound epithelization. In view of the complexity and high cost of BCP, it should be considered the possibility of their use in patients with a neuroischemic form of DFS of different grades by WIfI classification.